Spike Protein Clearance: Treatments & Evidence Levels
Interventions proposed to neutralise, degrade or remove SARS-CoV-2 spike protein, grouped by the strongest evidence behind each one. No treatment is established for clearing spike protein.
Treatments by evidence level
Tested in randomised trials
Randomised trials or regulatory review exist, but for acute COVID-19 or prophylaxis. None has been shown in a trial to clear persistent or vaccine-derived spike.
Pemivibart (INV-202)
Monoclonal antibody · FDA-authorized
Neutralizes spike; prevents ACE2 binding
Status: Authorized for immunocompromised pre-exposure prophylaxis
Limitations: Not approved for long COVID or vaccine-spike clearance
Sotrovimab
Monoclonal antibody · FDA-authorized
Spike neutralization (conserved epitope)
Status: Authorization withdrawn in many regions (variant escape)
Limitations: Acute COVID-19 only; limited variant coverage
Evusheld (tixagevimab/cilgavimab)
Monoclonal antibody combo · FDA-authorized
Dual spike neutralization
Status: EU authorization reduced/withdrawn due to variant escape
Limitations: Prophylaxis only; not for established spike persistence
Ivermectin
Antiparasitic · RCT negative/mixed
Docks to spike RBD-ACE2 interface (in silico/docking)
Status: Not recommended for COVID-19 (major RCTs negative)
Limitations: Docking study only; clinical RCTs failed primary endpoints
Quercetin
Flavonoid · RCT negative/mixed
TMPRSS2 inhibition; proposed ACE2/spike interface disruption (docking)
Status: OTC supplement; some meta-analyses for acute COVID
Limitations: Bioavailability poor; long COVID RCT data lacking
Colchicine
Anti-inflammatory · RCT negative/mixed
Anti-inflammatory; indirect reduction of spike-mediated inflammation
Status: Acute COVID trials mixed; not spike-directed
Limitations: Does not directly block or degrade spike
Azithromycin
Antibiotic · RCT negative/mixed
Proposed CD147 pathway interference (contested target)
Status: Acute COVID trials generally negative
Limitations: Not spike-specific; CD147 as a spike coreceptor is itself scientifically contested
Nirmatrelvir/ritonavir (Paxlovid)
Antiviral · FDA-approved (COVID-19)
Inhibits viral replication; may reduce spike production during active infection
Status: Approved acute COVID-19; long COVID prevention trials mixed
Limitations: Not designed for vaccine-derived spike clearance
Remdesivir
Antiviral · FDA-approved (COVID-19)
Reduces viral replication → less neoantigen production
Status: Hospitalized COVID-19
Limitations: No role in established spike persistence without active infection
Trials under way
Registered trials in Long COVID or post-vaccination illness; results pending.
SPEAR Trial (spike-directed apheresis)
Clinical trial · Ongoing trial
Protocolized spike reduction via apheresis
Status: Recruiting
Limitations: Results pending
Metformin
Autophagy inducer (off-label proposals) · Ongoing trial
Upregulates autophagy; proposed spike aggregate clearance
Status: NCT03996538 (vaccine response); long COVID interest
Limitations: Autophagy hypothesis; no completed long COVID spike-clearance RCT
NIH RECOVER
Research program · Ongoing trial
Multi-intervention long COVID trials
Status: Ongoing
Limitations: Not exclusively spike-targeted
Case series or pilot studies
Small, usually uncontrolled human studies. They can suggest a signal but cannot show that the treatment caused any improvement.
Therapeutic apheresis / plasmapheresis
Blood purification · Case series / pilot
Physical removal of circulating spike, autoantibodies, lipids
Status: SPEAR trial ongoing; Achleitner et al. long-COVID pilot
Limitations: No large RCT; invasive; symptom improvement in subsets only
N-Acetylcysteine (NAC)
Antioxidant / mucolytic · Case series / pilot
Thiol/disulfide exchange weakens spike-ACE2 binding affinity; glutathione precursor
Status: Used off-label; COVID-19 pilot studies
Limitations: In vitro binding-affinity data; heterogeneous clinical endpoints
Anti-CD147 antibody (meplazumab)
Monoclonal antibody · Case series / pilot
Blocks CD147–spike interaction
Status: Investigated in China for acute COVID
Limitations: CD147 as a direct spike-binding receptor is disputed by independent replication studies; limited Western regulatory approval
NRICM101 (traditional formula)
Herbal compound · Case series / pilot
Neurovascular protection in spike-administered hACE2 mice
Status: Investigated for brain fog in animal models
Limitations: Animal data; limited Western RCTs
Hyperbaric oxygen (HBOT)
Adjunct therapy · Case series / pilot
Tissue oxygenation; proposed neurovascular recovery
Status: Pilot long COVID studies
Limitations: Does not directly degrade spike; expensive
Low-dose naltrexone (LDN)
Immunomodulator · Case series / pilot
Immune modulation in long COVID (not spike-specific)
Status: Off-label use reported
Limitations: No spike degradation/blockade demonstrated
Lab-only (cell, enzyme or computer studies)
Activity against spike shown in a test tube, cell culture or docking model. No human data showing spike clearance.
Nattokinase
Protease supplement · In vitro / in silico only
In vitro degradation of recombinant spike at 2.5–25 µg/mL
Status: Dietary supplement; not FDA-approved as drug
Limitations: No human RCT for spike clearance; bleeding risk in pregnancy
Bromelain
Protease supplement · In vitro / in silico only
Spike degradation and competitive inhibition of spike–ACE2 binding
Status: OTC supplement
Limitations: Limited spike-specific human data; bleeding caution in pregnancy
Curcumin
Polyphenol · In vitro / in silico only
Virtual screening indicates spike/ACE2 binding inhibition
Status: Supplement
Limitations: Poor bioavailability; no spike-clearance RCT
Spermidine / resveratrol
Autophagy-promoting nutraceuticals · In vitro / in silico only
Autophagy upregulation
Status: Supplements
Limitations: No clinical spike-clearance validation
Theoretical
Proposed in reviews or from mechanism alone, without direct experimental data on spike.
Lumbrokinase / serrapeptase
Fibrinolytic enzymes · Theoretical / review only
Fibrin degradation; proposed microclot clearance
Status: Supplements; used off-label in some protocols
Limitations: No RCT for long COVID; indirect mechanism vs. direct spike degradation
Nicotine / α7nAChR agonism
Cholinergic modulator · Theoretical / review only
α7nAChR agonism to counteract spike-mediated receptor downregulation; anti-inflammatory
Status: Hypothesis; not standard of care
Limitations: Addiction liability; limited long COVID clinical trials
Rapamycin (sirolimus)
mTOR inhibitor / autophagy inducer · Theoretical / review only
Autophagy enhancement; proposed clearance of spike aggregates
Status: Investigational; immunosuppression limits use
Limitations: No human long COVID RCT; immunosuppressive
Intermittent fasting / caloric restriction
Lifestyle intervention · Theoretical / review only
Fasting-induced autophagy; proposed spike clearance
Status: Proposed in autophagy literature
Limitations: No controlled long COVID fasting RCT
Compare all interventions
Interventions claimed to block spike–receptor binding, degrade spike protein, or clear circulating spike/autoantibodies. Clinical support tiers reflect published RCTs, authorization status, or preclinical data only.
| Claimed mechanism | Limitations | Source | ||||||
|---|---|---|---|---|---|---|---|---|
| Pemivibart (INV-202)Track on OSMF Research Tracker → | Monoclonal antibody | Receptor/entry blockade | block | FDA-authorized | No | Neutralizes spike; prevents ACE2 binding | Not approved for long COVID or vaccine-spike clearance | |
| SotrovimabTrack on OSMF Research Tracker → | Monoclonal antibody | Receptor/entry blockade | block | FDA-authorized | No | Spike neutralization (conserved epitope) | Acute COVID-19 only; limited variant coverage | |
| Evusheld (tixagevimab/cilgavimab)Track on OSMF Research Tracker → | Monoclonal antibody combo | Receptor/entry blockade | block | FDA-authorized | No | Dual spike neutralization | Prophylaxis only; not for established spike persistence | |
| Therapeutic apheresis / plasmapheresisTrack on OSMF Research Tracker → | Blood purification | Enzymatic or physical clearance | clear | Case series / pilot | Yes | Physical removal of circulating spike, autoantibodies, lipids | No large RCT; invasive; symptom improvement in subsets only | Achleitner M, et al. (2023)Opens in new tabClinicalTrials.gov (2024)Opens in new tab |
| SPEAR Trial (spike-directed apheresis)Track on OSMF Research Tracker → | Clinical trial | Enzymatic or physical clearance | clear | Ongoing trial | Yes | Protocolized spike reduction via apheresis | Results pending | ClinicalTrials.gov (2024)Opens in new tab |
| NattokinaseTrack on OSMF Research Tracker → | Protease supplement | Enzymatic or physical clearance | degrade | In vitro / in silico only | Yes | In vitro degradation of recombinant spike at 2.5–25 µg/mL | No human RCT for spike clearance; bleeding risk in pregnancy | Tanikawa T, et al. (2022)Opens in new tab |
| BromelainTrack on OSMF Research Tracker → | Protease supplement | Enzymatic or physical clearance | degrade | In vitro / in silico only | Yes | Spike degradation and competitive inhibition of spike–ACE2 binding | Limited spike-specific human data; bleeding caution in pregnancy | Sagar S, et al. (2021)Opens in new tab |
| Lumbrokinase / serrapeptaseTrack on OSMF Research Tracker → | Fibrinolytic enzymes | Enzymatic or physical clearance | indirect | Theoretical / review only | Yes | Fibrin degradation; proposed microclot clearance | No RCT for long COVID; indirect mechanism vs. direct spike degradation | Halma MTJ, Marik PE, Saleeby YM (2024)Opens in new tab |
| IvermectinTrack on OSMF Research Tracker → | Antiparasitic | Receptor/entry blockade | block | RCT negative/mixed | No | Docks to spike RBD-ACE2 interface (in silico/docking) | Docking study only; clinical RCTs failed primary endpoints | Various (2020)Opens in new tab |
| QuercetinTrack on OSMF Research Tracker → | Flavonoid | Receptor/entry blockade | block | RCT negative/mixed | Yes | TMPRSS2 inhibition; proposed ACE2/spike interface disruption (docking) | Bioavailability poor; long COVID RCT data lacking | Various (2022)Opens in new tab |
| Nicotine / α7nAChR agonismTrack on OSMF Research Tracker → | Cholinergic modulator | Anti-inflammatory / immunomodulatory | both | Theoretical / review only | Yes | α7nAChR agonism to counteract spike-mediated receptor downregulation; anti-inflammatory | Addiction liability; limited long COVID clinical trials | Tillman TS, Chen Q, Bondarenko V, Coleman JA, Xu Y, Tang P (2023)Opens in new tabVarious (2023)Opens in new tab |
| N-Acetylcysteine (NAC)Track on OSMF Research Tracker → | Antioxidant / mucolytic | Anti-inflammatory / immunomodulatory | both | Case series / pilot | Yes | Thiol/disulfide exchange weakens spike-ACE2 binding affinity; glutathione precursor | In vitro binding-affinity data; heterogeneous clinical endpoints | Various (2022)Opens in new tab |
| CurcuminTrack on OSMF Research Tracker → | Polyphenol | Anti-inflammatory / immunomodulatory | indirect | In vitro / in silico only | Yes | Virtual screening indicates spike/ACE2 binding inhibition | Poor bioavailability; no spike-clearance RCT | Various (2020)Opens in new tab |
| ColchicineTrack on OSMF Research Tracker → | Anti-inflammatory | Anti-inflammatory / immunomodulatory | indirect | RCT negative/mixed | No | Anti-inflammatory; indirect reduction of spike-mediated inflammation | Does not directly block or degrade spike | |
| MetforminTrack on OSMF Research Tracker → | Autophagy inducer (off-label proposals) | Autophagy induction | clear | Ongoing trial | Yes | Upregulates autophagy; proposed spike aggregate clearance | Autophagy hypothesis; no completed long COVID spike-clearance RCT | Halma MTJ, Marik PE, Saleeby YM (2024)Opens in new tab |
| Rapamycin (sirolimus)Track on OSMF Research Tracker → | mTOR inhibitor / autophagy inducer | Autophagy induction | clear | Theoretical / review only | Yes | Autophagy enhancement; proposed clearance of spike aggregates | No human long COVID RCT; immunosuppressive | Halma MTJ, Marik PE, Saleeby YM (2024)Opens in new tab |
| Spermidine / resveratrolTrack on OSMF Research Tracker → | Autophagy-promoting nutraceuticals | Autophagy induction | clear | In vitro / in silico only | Yes | Autophagy upregulation | No clinical spike-clearance validation | Halma MTJ, Marik PE, Saleeby YM (2024)Opens in new tab |
| Intermittent fasting / caloric restrictionTrack on OSMF Research Tracker → | Lifestyle intervention | Autophagy induction | clear | Theoretical / review only | Yes | Fasting-induced autophagy; proposed spike clearance | No controlled long COVID fasting RCT | Halma MTJ, Marik PE, Saleeby YM (2024)Opens in new tab |
| AzithromycinTrack on OSMF Research Tracker → | Antibiotic | Receptor/entry blockade | block | RCT negative/mixed | No | Proposed CD147 pathway interference (contested target) | Not spike-specific; CD147 as a spike coreceptor is itself scientifically contested | |
| Anti-CD147 antibody (meplazumab)Track on OSMF Research Tracker → | Monoclonal antibody | Receptor/entry blockade | block | Case series / pilot | No | Blocks CD147–spike interaction | CD147 as a direct spike-binding receptor is disputed by independent replication studies; limited Western regulatory approval | Wang K, et al. (2020)Opens in new tab |
| Nirmatrelvir/ritonavir (Paxlovid)Track on OSMF Research Tracker → | Antiviral | Antiviral (indirect) | indirect | FDA-approved (COVID-19) | Yes | Inhibits viral replication; may reduce spike production during active infection | Not designed for vaccine-derived spike clearance | |
| RemdesivirTrack on OSMF Research Tracker → | Antiviral | Antiviral (indirect) | indirect | FDA-approved (COVID-19) | No | Reduces viral replication → less neoantigen production | No role in established spike persistence without active infection | |
| NIH RECOVERTrack on OSMF Research Tracker → | Research program | Multi-modal research program | indirect | Ongoing trial | Yes | Multi-intervention long COVID trials | Not exclusively spike-targeted | NIH RECOVER Initiative (2024)Opens in new tab |
| NRICM101 (traditional formula)Track on OSMF Research Tracker → | Herbal compound | Multi-modal research program | indirect | Case series / pilot | Yes | Neurovascular protection in spike-administered hACE2 mice | Animal data; limited Western RCTs | Chang CC, et al. (2024)Opens in new tab |
| Hyperbaric oxygen (HBOT)Track on OSMF Research Tracker → | Adjunct therapy | Anti-inflammatory / immunomodulatory | indirect | Case series / pilot | Yes | Tissue oxygenation; proposed neurovascular recovery | Does not directly degrade spike; expensive | |
| Low-dose naltrexone (LDN)Track on OSMF Research Tracker → | Immunomodulator | Anti-inflammatory / immunomodulatory | indirect | Case series / pilot | Yes | Immune modulation in long COVID (not spike-specific) | No spike degradation/blockade demonstrated |
Clinical support legend
- FDA-approved/authorized — Regulatory approval for acute COVID-19 or prophylaxis; not necessarily long COVID or vaccine-spike clearance.
- RCT positive/negative — Randomized trial outcomes for claimed indication.
- Case series / pilot — Small human studies (e.g., Achleitner apheresis long-COVID cohort).
- In vitro only — No robust human efficacy (e.g., nattokinase 2.5–25 µg/mL cell-free degradation).
- Theoretical — Review or pharmacogenomic rationale without clinical validation.
Clinical caution
No intervention is established standard of care for vaccine-derived spike clearance. Nattokinase and bromelain carry bleeding-risk cautions in pregnancy/breastfeeding.
- Tanikawa T, et al. Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2. Molecules (2022). doi:10.3390/molecules27175405
- Sagar S, et al. Bromelain inhibits SARS-CoV-2 infection via targeting ACE-2, TMPRSS2, and spike protein. Clinical and Translational Medicine (2021). doi:10.1002/ctm2.281
- Halma MTJ, Marik PE, Saleeby YM Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology. Endocrine and Metabolic Science (2024). doi:10.1016/j.endmts.2024.100163
- Achleitner M, et al. Clinical improvement of long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis. Molecular Psychiatry (2023). doi:10.1038/s41380-023-02084-1
- ClinicalTrials.gov SPEAR Trial — spike protein apheresis research. Clinical trial registry (2024)
- NIH RECOVER Initiative RECOVER — Researching COVID to Enhance Recovery. NIH program (2024)